{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T01:53:32Z","timestamp":1773712412954,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>This open\u2010label, multicenter, phase I therapeutic protein\u2010drug interaction study was designed to evaluate the potential effect of guselkumab, a fully human anti\u2010interleukin\u201023 immunoglobulin G1 lambda monoclonal antibody, on the pharmacokinetics of a cocktail of representative cytochrome P450 (CYP) probe substrates (midazolam (CYP3A4), S\u2010warfarin (CYP2C9), omeprazole (CYP2C19), dextromethorphan (CYP2D6), and caffeine (CYP1A2)). Fourteen participants with psoriasis received a single subcutaneous dose of guselkumab 200\u00a0mg on day 8 and an oral probe cocktail on days 1, 15, and 36. Blood samples were collected for measuring plasma concentrations of these probe substrates on days 1, 15, and 36. No consistent trends in observed maximum plasma concentration and area under the curve from time 0 to infinity values of each probe CYP\u2010substrate before (day 1) and after guselkumab treatment (days 15 and 36) could be identified in each individual patient, suggesting that the use of guselkumab in patients with psoriasis is unlikely to influence the systemic exposure of drugs metabolized by CYP isozymes (CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2). The probe cocktail was generally well\u2010tolerated when administered in combination with guselkumab in patients with psoriasis.<\/jats:p><jats:p>Clinicaltrials.gov Identifiers: NCT02397382.<\/jats:p>","DOI":"10.1111\/cts.12807","type":"journal-article","created":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T20:59:24Z","timestamp":1589489964000},"page":"1217-1226","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Evaluating Potential Disease\u2010Mediated Protein\u2010Drug Interactions in Patients With Moderate\u2010to\u2010Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab"],"prefix":"10.1111","volume":"13","author":[{"given":"Yaowei","family":"Zhu","sequence":"first","affiliation":[{"name":"Janssen Research &amp; Development, LLC Spring House Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Spring House Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Spring House Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa","family":"Piantone","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Spring House Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathye","family":"Shu","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Spring House Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dion","family":"Chen","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Spring House Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honghui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Spring House Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenhua","family":"Xu","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Spring House Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amarnath","family":"Sharma","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC Spring House Pennsylvania USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"e_1_2_11_1_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.048884"},{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13670"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0730-x"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00702.x"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.10.862"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0804595"},{"key":"e_1_2_11_7_1","first-page":"5","article-title":"Emerging therapies in psoriasis: a systematic review","volume":"101","author":"Lee E.B.","year":"2018","journal-title":"Cutis"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.040"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6446(05)03638-X"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9285-6"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2423-3"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.302"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010510-100510"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.561"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.052225"},{"key":"e_1_2_11_18_1","unstructured":"TREMFYA\u00ae (Guselkumab) [package insert].Janssen Biotech Inc Horsham PA USA; November 2019."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00229-7"},{"key":"e_1_2_11_20_1","unstructured":"Zhu Y.et al.Use of phase 2 guselkumab exposure response relationship in psoriasis to inform phase 3 dose selection. 26th European Academy of Dermatology and Venereology Congress September 13\u201317 2017 Geneva Switzerland (Poster 1827)."},{"key":"e_1_2_11_21_1","volume-title":"Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications","author":"Gabrielsson J.","year":"2007"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.2307\/3001634"},{"key":"e_1_2_11_23_1","volume-title":"Practical Nonparametric Statistics","author":"Conover W.J.","year":"1999"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1063"},{"key":"e_1_2_11_25_1","unstructured":"US Food and Drug Administration (FDA) Guidance for Industry.Clinical drug interaction studies \u2014 study design data analysis and clinical implications. 2017.<https:\/\/www.fda.gov\/media\/82734\/download>. Accessed September 3 2019."},{"key":"e_1_2_11_26_1","unstructured":"US Food and Drug Administration.Clinical pharmacology review. 761061Orig1s000. [BLA#761021] 2016. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761061Orig1s000MultidisciplineR.pdf>. Accessed February 25 2020."},{"key":"e_1_2_11_27_1","unstructured":"US Food and Drug Administration.Clinical pharmacology review. 761067Orig1s000. [BLA#761027] 2017. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/761067Orig1s000MultdisciplineR.pdf>. Accessed February 25 2020."},{"key":"e_1_2_11_28_1","unstructured":"US Food and Drug Administration.Clinical pharmacology review. 761105Orig1s000. [BLA#761105] 2019. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761105Orig1s000MultidisciplineR.pdf>. Accessed February 25 2020."},{"key":"e_1_2_11_29_1","first-page":"127","article-title":"Oncostatin M down\u2010regulates basal and induced cytochromes P450 in human hepatocytes","volume":"285","author":"Guill\u00e9n M.I.","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90056-9"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.003459"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015835215945"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.DMPK-11-RG-078"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003261333"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcts.12807","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12807","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.12807","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T09:30:28Z","timestamp":1693819828000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.12807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/cts.12807"],"URL":"https:\/\/doi.org\/10.1111\/cts.12807","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,28]]},"assertion":[{"value":"2020-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}